Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
7.94 USD +3.12% Intraday chart for Tango Therapeutics, Inc. -3.41% -19.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
H.C. Wainwright Adjusts Price Target on Tango Therapeutics to $17 From $16, Keeps Buy Rating MT
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index CI
Transcript : Tango Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM
Piper Sandler Initiates Tango Therapeutics With Overweight Rating MT
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says RE
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348 MT
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers CI
B. Riley Starts Tango Therapeutics With Buy Rating, $16 Price Target MT
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q3 Revenue $10.7M MT
Tango Therapeutics, Inc. Announces Board Changes CI
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday MT
Tango Therapeutics Discloses Boxer Capital Acquired 1.3 Million Shares; Tango Stock Jumps in Premarket Activity MT
Tango Therapeutics Receives FDA Clearance to Start the TNG348 Phase 1/2 Clinical Study CI
Tango Therapeutics Says FDA Cleared Application for Investigational Cancer Treatment TNG348 MT
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for Tng348, A Novel Usp1 Inhibitor for the Treatment of Brca1/2-Mutant and Other HRD+ Cancers CI
Tango Therapeutics Files Prospectus for Sale of 15.5 Million Shares MT
Tango Therapeutics, Inc. Announces Board Changes CI
Tango Therapeutics, Inc. announced that it has received $80.016604 million in funding CI
HC Wainwright Adjusts Tango Therapeutics Price Target to $16 From $11, Maintains Buy Rating MT
Tango Therapeutics, Inc. announced that it expects to receive $80 million in funding CI
Top Premarket Gainers MT
Chart Tango Therapeutics, Inc.
More charts
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.94 USD
Average target price
17.57 USD
Spread / Average Target
+121.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Tango Therapeutics, Inc. - Nasdaq
  4. News Tango Therapeutics, Inc.
  5. Tango Therapeutics : SVB Leerink Initiates Coverage on Tango Therapeutics With Outperform Rating, $25 Price Target